NFKB1 and chronic kidney disease: FXR reduces TNFα and downstream Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), not only successfully halting acute kidney injury progression to chronic kidney disease (CKD) but also improving glomerulosclerosis and interstitial fibrosis while suppressing the expression of fibrogenic genes [50].